

COPD/Bronchiectasis Patient Symptoms Overview

With high hospital readmissions and antibiotic resistance being such an issue – especially among the COPD population – other treatment options are worth considering

If you have COPD/Respiratory patients that have had:



✓ Daily productive (mucus) cough for at least 6 continuous months

OR



✓ Frequent (i.e. more than 2/year) exacerbations/chest infections requiring antibiotic therapy

AND



✓ Well-documented failure of other treatments to adequately mobilize retained secretions/airway clearance (chest physiotherapy, postural drainage, flutter valve, Acapella, pharmacological, etc.) and the effectiveness of the treatment

These patients may have BRONCHIECTASIS



✓ and, if confirmed via a CT scan,

may be eligible for the AffloVest through Medicare, Medicaid, private insurance and the U.S. Department of Veterans Affairs /Tricare.*

Patient Demographics

It is estimated that bronchiectasis is under diagnosed due to its variable symptoms. Bronchiectasis increases with age and is more common in women than in men. The COPD Foundation estimates there are as many as 8 million undiagnosed bronchiectasis patients in the USA. In one study it was found that in the COPD patients that were identified with the frequent exacerbator phenotype (≥ 2 exacerbations per year), almost 93% had bronchiectasis.¹

Why AffloVest:

The AffloVest offers physicians and patients an airway clearance medical device that helps clear the chest airways. The AffloVest gives patients a device that they can use at home or anywhere on a preventative type of therapy which could help to prevent mucus buildup and subsequent lung infections. In other words, if patients use this therapy as prescribed by their doctor, typically 1 to 2 times per day for just minutes a day at home, it may help prevent lung infections which lead to hospitalization and subsequent re-admissions. Because the AffloVest is quiet, portable, easy to use, and fully mobile during use, this device may more likely be used by an older patient population with bronchiectasis.

- AffloVest is different. It does not use air generator and air bladder technology first developed in the 1980's. No loud and heavy air generators. No air hoses and electrical cords to connect. With AffloVest's 21st century technology it gives doctors a new tool to help manage their COPD/bronchiectasis patients utilizing the latest in oscillation therapy, portability and mobility during use.
- The AffloVest features built-in oscillating modules that allow for freedom of movement to travel, go for a walk in the park, move around the house, or relax in front of the television. Patient home treatment plans can be customized using the targeted motors for specific lung lobes or chest wall zones using different levels of intensity.

* AffloVest requires a doctor's prescription for treatment by High Frequency Chest Wall Oscillation (HFCWO). The AffloVest has received the FDA's 510k clearance for U.S. market availability, and is approved for Medicare, Medicaid, and private health insurance reimbursement under the Healthcare Common Procedure Coding System (HCPCS) code E0483 – High Frequency Chest Wall Oscillation. The AffloVest is also available through the U.S Department of Veterans Affairs/Tricare. Patients must qualify to meet insurance eligibility requirements.

1. Bronchiectasis in Patients With COPD: An Irrelevant Imaging Finding or a Clinically Important Phenotype? Epaminondas Kosmas, MD; Silvia Dumitru, MD; Spiros Gkatzias, MD; Konstantinos Velentzas, MD; Serafeim Iossif, MD Obstructive Lung Diseases: COPD | October 2016

In Just Minutes a Day*
Clear your Chest with AffloVest.™

INTERNATIONAL
BIOPHYSICS
CORPORATION

MKT0032 Rev B

